CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 153 enrolled
Drug / intervention
Cisplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00500760
NCT00500760Phase 2Completed
CompareCT.gov

A Phase 2, Randomized Trial of Chemoradiation With or Without Panitumumab in Subjects With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Amgen·interventional·Posted Jul 13, 2007·Updated Oct 17, 2018

In Brief

A Phase 2 clinical trial evaluating Cisplatin, Standard Fractionation Radiotherapy, and 1 other intervention for Head and Neck Cancer and Squamous Cell Carcinoma. Completed, enrolled 153 participants.

Detailed Summary

The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer, Squamous Cell Carcinoma
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 13, 2007
Enrollment StartOct 1, 2007
Primary CompletionMar 29, 2011
Study CompletionApr 26, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 19.0 years ago

Interventions

Cisplatindrug

Administered intravenously (IV; in a vein)

Standard Fractionation Radiotherapyradiation

70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)

Panitumumabdrug

Administered intravenously